Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A study published in Surgery found 18F-fluorocholine positron emission tomography had better sensitivity for parathyroid localization than sestamibi or ultrasound. 18F-FCH-PET guided 83% of curative surgeries, compared with 24% for sestamibi and 35% for ultrasound.
Profits and dividends will be nice.
Put in drawer is smart.
Looking for blue chip at nasdaq level contradicts itself.
I’m betting on technology meeting market needs. I hope their vision can deliver on my knowledge.
Its also the case that a lot of what you suggest or imply is probably in the price anyway. At 70 cents the company is worth about 10 million USD, at a dollar its worth 14 million USD; these are not shabby figures for a company in Positrons state of development. Any real re-rating can only come after profits and dividends are reported and a return to the NASDAQ. Very few investors will touch a pink sheet company and the liquidity here sucks. If one has them its one to put in the bottom drawer and live in hope lol
If only the traders could look past what they perceive as hype.
Industry professionals see the future and we’re good. Watch and learn.
What updates? That story is getting long in the tooth now. Its time to realise that the hiring of these external bods is merely a exercise to promote the stock, there are no Pet scanner orders, and no accounts, no evidence of anything happening whatsoever other then nudges and winks that something may happen. These sort of companies are pink stocks for a reason, and until something happens its all stories.
FCH-PET shines in guiding parathyroid surgery
The study authors analyzed the clinical impact of PET imaging with a radiotracer called F-18 fluorocholine (FCH) for guiding parathyroid surgery in patients with cancer and compared the results with standard imaging with ultrasound or sestamibi scintigraphy. They found that F-18 FCH-PET was more accurate at identifying tumors and subsequently led to more surgical "cures."
CMS removes exclusion for non-oncologic PET
CMS published its CY 2022 MPFS Proposed Rule—including a significant change for nuclear medicine.
CMS proposes to remove the "exclusionary language" from Positron Emission Tomography (PET) Scans.
This will leave non-oncologic PET indications to the discretion of local Medicare Administrative Contractors (MACs).
CMS stated, "We believe that extending local contractor discretion for non-oncologic indications of PET provides an immediate avenue to potential coverage in appropriate candidates and provides a framework that better serves the needs of the Medicare program and its beneficiaries." New FDA-approved non-oncologic radiopharmaceuticals will be covered under MAC discretion.
We applaud CMS’s coverage decision, which results from years of work by SNMMI and our industry partners.
Let’s all stay tuned for updates from the company …..????
Sounds like their getting ready to kill it. You should be me more concerned if they can meet all the demand.
Sounds like their getting ready to get the begging bowl out -? fund raising to expand market share and develop their strategy.
Does this have anything to do with the other?
I’d like to see Positron educate shareholders on why diagnostic medicine is all in on PET imaging.
Perhaps ….one can speculate on this weeks press release ??
Positron Retains Healthcare Advisor I-Square Ventures to Implement Strategy and Expand Market Share
Niagara Falls, NY – July 15, 2021 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC) is pleased to announce today that it has retained the services of I- Square Ventures (“I-Square”) to refine the Company’s value proposition and further advance the go to market strategy within the nuclear medicine arena.
I-Square is a boutique growth strategy consulting firm that has developed growth strategies, execution processes, and technology solutions that have delivered billions of dollars in free cash flow growth for large public companies and small private companies in the Healthcare, Insurance and Technology industries.
Adel Abdullah, President of Positron stated: "Positron is at a significant inflection point and in an ideal position to capitalize on a very positive environment and outlook for PET technology. With many expected milestones for Positron, we believed bringing on board the expertise of a seasoned healthcare industry team in I-Square and its Managing Partner Dr. Chiranjeev “CJ” Bordoloi was important to further solidify our focus on strategy, sales and market penetration moving forward. Expanding our team strategically, and deepening our reach within the nuclear imaging industry, should greatly advance and accelerate our progress. We are very pleased to welcome a group of growth experts led by Dr. Bordoloi to our team at this exciting time for Positron.”
Dr. Chiranjeev “CJ” Bordoloi, Managing Partner or of I-Square Ventures, commented: “In our detailed and thorough due diligence cycle of analyzing players in the nuclear imaging industry, along with input from large healthcare institutional clients, we believe that Positron is uniquely positioned to grow market share and benefit as the industry experiences the advantages of migrating from SPECT to PET systems. While the superiority of PET technology over SPECT has long been known, pricing has previously been the main issue slowing this adoption. Positron has leveraged technology innovation to design efficiencies and reduce costs that make PET pricing comparable to SPECT, while at the same time providing superior diagnostic accuracy,
Agreed …..perhaps people should refrain from making COMMENTS based on their unsubstantiated negative speculation
I’m sure the company will unfold their story in the near future.
GLTA
Agreed but getting current should be there main concern
Positron Retains Healthcare Advisor I-Square Ventures to Implement Strategy and Expand Market Share
This is very positive.
Yes the summary was fine.
If only it addresses the tangibles rather than Wall Street mechanics.
PET is the pinnacle of the industry and this company has the product. Let’s see where they take it, I suspect it is much more than we understand.
Thank you for the summary . I hadnt checked on this in a while. Just caught my eye one day when I saw it up like 30% . Still no news from them and if by 9/28 they don't get current.... well we all know what that means. Guessing a lot of dumping will take place in aug/sep to try and salvage a few pennies.
A PR company called Skyline operating out of NYC has been puffing this but company has made no sales of its product in the past couple of years, and it only appears to have an agency for the PET scanner from a Chinese company called Nusoft. Their main income appears to be the servicing contracts for the existing 19 ? odd PET scanners that are out there, and their filing is NOT current. Talk is there preparing to make it so but its not at present. They also claim to be profitable and have no debt but its not possible to check this either. One stockholder, who bought in in 2015 era, appears to own a lot of it and he is losing heavily, even at the current price of under 1 USD. Speculative at best.
I've been in this since the rooney cyclotron days and figured this is written off. However they seem to still be alive.. are they current on their filings
You all are seeing what we already know.
PET getting all the attention these days.
PET impact on Alzheimer's disease
June 2, 2021 -- PET imaging of patients to detect Alzheimer's disease may be effective in minutes rather than hours after they are injected with a radiotracer, according to research published May 28 in the Journal of Nuclear Medicine. The finding suggests "early frame" PET may reduce imaging costs and burden on patients and their families.
Nice to see some recognition brewing.
Gale force tailwinds are gusting cardiology practices into the cardiac PET market.
Positron Corp. couldn't have chose a better time to scale up their efforts again:
1.) https://www.healthimaging.com/topics/molecular/guide-coronary-artery-disease-pet-myocardial-blood-flow
"Two of molecular imaging’s top professional organizations on Wednesday published new guidelines for using positron emission tomography to better diagnose coronary artery disease.
Measuring myocardial blood flow as part of perfusion imaging has been a key development in the field and should be part of providers’ daily workflow, experts said in a statement on Thursday.
......
“While there are many excellent publications on all aspects of PET blood flow quantification, we felt that there existed a gap, especially for nuclear physicians practicing in non-academic centers,” Timothy Bateman, MD, a lead author of the writing committee composed of world-renowned leaders in cardiac PET.
2.) Bracco Diagnostics Inc. Announces New Partnership to Increase Access to Cardiac PET Imaging
https://cardiology2.com/bracco-diagnostics-inc-announces-new-partnership-to-increase-access-to-cardiac-pet-imaging/
"This new program, the Bracco Mobile Isotope Service, will enable more patient care sites, such as community hospitals, physician practices and outpatient imaging centers, to provide cardiac PET imaging."
An impressive camera not surprised to see stock rising.
file:///var/mobile/Library/SMS/Attachments/ee/14/710FAF3A-94B2-4C26-9F44-20D61F7AE0E1/Attrius_FrontLeft_reflection.png
Great image of the Positron ATTRIUS scanner!!
April 12, 2021
Re: Q1 2021 Update
Dear Positron Shareholders,
As announced last month we are pleased to have retained Skyline Corporate Communications Group as Positron’s investor relations liaison. Skyline will play a large role in our corporate communication efforts to introduce and inform new, perspective and current shareholders of our advancements. We have worked with them on strategically presenting our message to the financial community in a compelling manner while laying out our vision for Company growth and expected milestones. In only the short time since engagement have been introduced to a number of parties within the investment community who are interested in learning more and potentially joining our future as stakeholders. We believe the team we have established over the past quarter to expand our public stance will greatly improve Positron’s ability to deliver value to all.
There is little doubt that the current and future trend in the nuclear cardiology industry is shifting from SPECT to PET imaging/diagnostics. This evolution to PET can be attributed to a number of factors such as; improved reimbursement, demand for coronary flow analysis and an overall shift towards better medicine, which takes into account practices seeking a competitive advantage in PET vs. SPECT in the marketplace. An additional key issue which is impacting PET comes from the challenges underway in the SPECT industry due to a lack of radiopharmaceutical supply that is limiting the usability of this lesser yet more utilized imaging modality throughout the world. PET is the proven superior nuclear cardiac technology and Positron is well positioned to meet this new demand of the nuclear cardiology industry.
We continue to focus on increasing sales with a number of opportunities in the pipeline. We are actively seeking a Head of Sales to expand our target reach. We also have made progress on company structure, governance and determining our path to return to being a fully-reporting public company; we will continue to make this a priority of the corporate side of our business.
All at Positron appreciate the support we receive and remain more confident than ever that Positron can and will be instrumental in participating and benefiting from the new demand for cardiac PET imaging.
We will have more to expand on in coming weeks/months and will disseminate any and all material information as it develops. Thank you for your loyal support as Positron enters an exciting new phase of rebuilding and growth.
Thank you
Best Regards,
Adel Abdullah Positron Corporation President
WWW.POSITRON.COM
Why meaningless?
It’s just where people exchange shares where they want.
I wish we could buy more.
Nothing to see here. Usual flip up on low vol to 1 dollar and then back to 20 cents. The drop on super low volume also. The quote is meaningless
Great to see people realizing the value of an undiscovered company !!!
The market is starting to see what we know is coming in PET.
Keep up the good work.
Academics continue to further what's possible in this space:
https://physicsworld.com/a/deep-learning-enables-safer-heart-scans-with-lower-radiotracer-dose/
The market fundamentals are definitely turning our way, the company keeps saying they are working on coming out of the dark, and there is definitely sustained buying interest methodically walking up the bid.
I believe the Flourpiridaz, F-18 approval, now expected in 2013, will be the watershed moment for cardiac PET this company has been waiting for over a decade.
Speculating that this is start of a trend.
Interesting there hasn't been any PR issued for this system sale. Has the system been delivered yet?
Also,someone is buying at the ask today.
The market is coming to us for both system and stock sales, I hope the company files their Form 10 and begins communicating with investors again soon.
Actually it’s not my decision it comes from above. Only dedicated PET, 2D, history of performance and I’m sure price was key.
There are no competitors.
That's great news for Positron! Would you mind summarizing why you decided on the Attrius versus PET cameras from more prominent competitors?
We are buying an Attrius. Finally getting into the game.
FDA approves Bracco’s CardioGen infusion system.
Very positive for PET systems.
This could be a real gem in the making.
Markets are forward looking, in the meantime, the company is working on getting its filings back up to date to become SEC reporting again, so its better prepared and more transparent when customers and investors come looking.
We do know the company did at least sell a couple of new PET systems when they issued press releases indicating new system sales in 2018.
As I understand it, the market availability of the RUBY-FILL Rubidium-82 generator, did help increase the use of cardiac PET for myocardial perfusion imaging (MPI) for elderly and obese patients. Rubidium-82 has a short half life and can only be used for completing MPI at rest, and under pharmacologically induced stress. Pharmocologically induced stress is only preffered for obese or immobile that aren't capable of walking on the treadmill to create more natural exercise induced stress.
https://www.globenewswire.com/news-release/2019/12/11/1959574/0/en/Jubilant-Receives-Favorable-Ruling-from-the-U-S-Courts-for-RUBY-FILL.html
I think the availability of longer half life, Fluorpiridaz F-18, will be the tipping point where cardiac PET will be preferred over SPECT for all patient populations, and the economics will also then become favorable for small and medium sized cardiology offices to replace their SPECT equipment with cardiac PET machines.....and the Positron Attrius PET is currently the only one that doesn't also include expensive to operate and maintain CT system as well....which isn't needed for PET MPI:
https://www.mobilecardiacpet.com/pet-mpi-statistics/
I bought near the lows in 2018 and have been continuing to accumulate
into the teens because I believe the company is well positioned to benefit from this coming seachange in cardiac imaging modalities.....and I think there's a good chance of this stock being worth dollars when the market sees the opportunity coming their way as well.
Make that 3 months.
Post covid demand 10x.
3 year wait, any shortcut?
I agree, cardiac PET is already gaining significant traction with the coalition of industry organizations that teamed up to defend medicare reimbursement rates for cardiac PET last year.
It looks like cardiac PET will be ready to overtake SPECT for myocardial perfusion imaging (MPI) when Flurpiridaz F-18 gets FDA approval, now expected in early 2023. Thousands of PET cameras will be needed and Positron is well positioned to benefit when that demand comes.
Im Long here still, been picking up shares at this discount for a while, this will take off one day here next year and under $1.00 will be a gift
SNMMI and Partners Host Congressional Briefing on the Groundbreaking Potential of Radiopharmaceuticals in Oncology and Need for Expanded Patient Access
https://www.snmmi.org/NewsPublications/NewsDetail.aspx?ItemNumber=34616
SNMMI and Partners Host Congressional Briefing on the Groundbreaking Potential of Radiopharmaceuticals in Oncology and Need for Expanded Patient Access
September 17, 2020
Yesterday, SNMMI and its coalition partners, Medical Imaging & Technology Alliance (MITA) and Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR) hosted a virtual briefing for Capitol Hill staff yesterday with leading physicians to discuss the extraordinary and growing impact of positron emission tomography (PET) and nuclear medicine in cancer treatment, as well as the importance of expanding patient access to these drugs through passage of the Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 (H.R. 3772).
The briefing included presentations from Dr. David Mankoff, Gerd Muehllehner Professor of Radiology and Vice-Chair for Research of Radiology at the University of Pennsylvania’s Perelman School of Medicine, and Dr. Michael Roarke, Chair of the Division of Nuclear Medicine for the Mayo Clinic Arizona Department of Radiology and Medical Director at the Mayo Clinic’s Arizona Cyclotron Facility. The event also featured John D. (full name cannot be disclosed for privacy reasons), a prostate cancer patient who provided insights into his experience with nuclear medicine and its important impact on his treatment pathway.
Congressman Greg Murphy, M.D. (NC-3) – one of the cosponsors of H.R. 3772 – led off the briefing and noted: “Nuclear medicine is already playing a growing role in diagnosing advanced disease, including prostate and breast cancer. Passage of H.R. 3772 will give patients and their physicians the tools they need to diagnose life-threatening diseases early, when they are most treatable– a key improvement that will reduce downstream costs and, more importantly, save lives.”
Following the Congressman’s remarks, patient John D. shared his personal experience with nuclear medicine and the positive difference it made in his fight against prostate cancer: “When my Prostate-Specific Antigen (PSA) levels spiked, I assumed the worst, but thought it was best to know the truth as quickly as possible. Reviewing my PET scan with my doctor, I worried that cancer would be everywhere, but in fact, there was only a single small spot of red– no bigger than a penny, indicating my cancer. Twenty-one days later, I went in for radiation therapy and the results from the PET scan allowed doctors to target the precise spot. In the months following, my PSA levels dropped significantly. My PET scan not only guided my treatment but helped alleviate my anxiety. Without that information to guide my treatment, I’m not sure where I’d be."
After John offered his perspective as a cancer patient, Dr. Michael Roarke drew on his more than 24 years of experience in nuclear medicine to provide an overview of PET technology and its growing influence on the clinical mainstream. “The impact of this powerful diagnostic tool on patient care and the field of cancer treatment is truly extraordinary,” noted Roarke. “Expanding access to the most advanced and effective PET radiopharmaceuticals would strengthen America’s healthcare system and enhance our ability to diagnose advanced illnesses earlier and with greater accuracy.”
As the director of the PET Center at the Perelman School of Medicine at the University of Pennsylvania, Dr. David Mankoff elaborated on how PET radiopharmaceuticals are being used to change the way breast cancer is treated: “Diagnostic PET radiopharmaceuticals are capable of identifying metastatic breast cancer at an earlier stage and can determine if a prescribed treatment is working. Although this information can help guide treatment decisions and improve patient outcomes, patients and their providers continue to encounter severe roadblocks when seeking coverage for these innovative diagnostic approaches.”
Following-up on Dr. Mankoff’s remarks, Sue Bunning, MITA Industry Director of Molecular Imaging & PET, closed the briefing with an overview of Medicare’s current reimbursement policy and why it undermines patient access to innovative radiopharmaceutical diagnostics:
“Unfortunately, the Centers for Medicare and Medicaid Services currently treats PET radiopharmaceuticals, including the drugs needed for diagnostic scans, as part of the packaged cost of the procedure in the hospital outpatient setting. This structure disincentivizes the utilization of many radiopharmaceuticals for Medicare patients, leading to limited patient access and stifled innovation. The Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 (H.R. 3772) represents a legislative solution that would address structural flaws in the current payment methodology and grant greater access to life-saving PET diagnostic radiopharmaceuticals for patients,” Bunning concluded.
A clip of of Drs. Roarke's and Mankoff's presentations may be viewed here. Currently the bill has 23 co-sponsors in the House.
With the end of the current legislative session fast approaching, we need your help!
Please act today: Send a letter of support for H.R. 3772 to your member of Congress. For more information on SNMMI's efforts on H.R. 3772, click here.
F-18 trial and approval will be a huge score for PET.
F-18 will be the widespread end of life of SPECT for MPI.
Lantheus indicates the Flurpiridaz F-18 trial timeline has been extended due to COVID-19:
https://finance.yahoo.com/news/edited-transcript-lnth-oq-earnings-121431193.html
"Turning now to Flurpiridaz F 18, our novel PET cardiac imaging agent. Our development and commercialization partner, GE Healthcare, has informed us that the second Phase III trial continues. However, new patient enrollment has been delayed due to the impact of the pandemic. GE Healthcare intends to resume enrollment in this quarter and expects to complete enrollment by mid-2021, and, assuming regulatory approval, begin commercialization in early 2023."
Must see TV:
https://www.dicardiology.com/videos/video-better-flow-quantification-and-rise-pet-among-trends-cardiac-nuclear-imaging
This has been a very slow pitch, right over home plate. This company had taken too many swings before the ball reached the batter and struck out with a bankruptcy reorganization, but I do believe the the expected approval of Fluorpiridaz-18 later this year is really going to open things up for this company.
I am long and patiently waiting.
Avid’s F-18 marker approved for Alzheimer disease studies using PET.
There has been some movement on the engine front too with Nasa giving another obscure company money to develop a Positron breaking system for their star shot program. Its all very early days of course.
Nice to see interest in Positron.
The value is much higher.
Betting on the stock gaining more interest as the imaging industry speeds towards PET.
Watching closely.
Followers
|
166
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
19499
|
Created
|
07/13/03
|
Type
|
Free
|
Moderators |
Symbol: OTC: POSC
Positron is a nuclear medicine healthcare company specializing in the business of cardiac Positron Emission Tomography (PET). Cardiac PET is the superior method in diagnostic nuclear imaging for the detection of coronary artery disease (CAD), a leading cause of death in the United States. Positron’s products and services empower healthcare providers to more accurately diagnose CAD and improve patient outcomes while practicing cost effective medicine.
Positron, a pioneer in nuclear cardiology for over 30 years, is establishing a unique position by vertically integrating the fragmented and limited supply environment that exists in the cardiac PET marketplace today. Positron’s approach is to provide nuclear cardiologists an end-to-end solution by offering award-winning imaging technology, clinical services, imaging agents and innovative financing packages conveniently from a single source. Positron's business approach will bring substantial advantages in accelerating the adoption of this superior modality and growth of the nuclear cardiology industry.
Positron Corporation is a publicly listed company. Shares of common stock of Positron Corporation are currently trading on the National Association of Securities Dealers, Inc.'s under the symbol POSC.
Key Business Components
PET Imaging System and Services
The Attrius®, dedicated PET imaging system, is optimized for cardiology. Positron's Attrius provides customers with state-of-the-art imaging technology for the diagnosis, treatment and prevention of cardiovascular disease. The Attrius is the only dedicated PET scanner in the world and was awarded Frost & Sullivan's Most Innovative Medical Device of the Year award as "the ideal solution for cardiologists and hospitals looking to add high accuracy, cost effective imaging technology." Positron complements its technology by offering comprehensive world-class clinical, technical and service support through their PosiStar™ customer care plan.
Financing Solutions
Positron provides customers with a variety of financing solutions for its full solutions model designed to minimize any barriers to entry, thus accelerating the expansion of cardiac PET and further securing Positron's current and future position in the market.
Market Opportunities
Nuclear medicine helps in the diagnosis, management and prevention of patients with cardiovascular disease (CVD). Radiopharmaceuticals are injected into a patient to provide the most accurate, non-invasive test for identifying narrowed coronary arteries, mild cholesterol build-up or diffuse coronary vascular disease; conditions that are responsible for almost all heart attacks. Cardiovascular disease is the leading cause of death in the United States and constitutes 17% of overall national health expenditures (Forecasting the Future of Cardiovascular Disease in the United States, American Heart Association, 2011). Direct CVD costs are projected to increase from $273 billion in 2010 to $818 billion in 2030, and indirect costs (due to lost productivity) will rise from $172 billion in 2010 to $276 billion in 2030.
Positron Emission Tomography (PET)
PET is a more advanced and accurate technology. In cardiac perfusion imaging, PET scanners, in particular Positron's Attrius, have superior sensitivity and specificity compared to that of SPECT cameras. PET also produces less radiation exposure and is capable of performing quantitative measurements. Cardiac PET imaging has been shown to provide a 50% reduction in invasive coronary arteriography and coronary artery bypass grafting, leading to a 30% costs savings and excellent clinical outcomes compared to SPECT (M.E. Merhige, M.D., et al. Journal Nuclear Medicine 2007; 48: 1069-1076).
The cardiac PET equipment market is much smaller than SPECT but has seen significant annual growth, of 25-30%, during the last decade. For many years, a major constraint for this market has been the high cost of PET and PET/CT scanners for cardiac studies. Positron has managed to reduce the buyers' barrier to entry by bringing to market the Attrius; the only cardiac dedicated PET system in the world. All other manufacturers (GE, Philips, Siemens) offer PET/CT systems that have a comparable performance of cardiac studies but have a 200% to 300% higher price, in relation to the Attrius. These same PET/CT systems also possess attributes not optimized or conducive for cardiac imaging.
Products
Attrius®
Attrius is the only FDA approved new dedicated PET scanner optimized for cardiac imaging.
The Attrius provides a robust, cardiac specific imaging software package designed to ensure effortless interpretation for today's most challenging clinical cases for nuclear cardiologists. This innovative software includes coronary artery overlay display, open architecture for new protocol development, customization and motion correction and the ability to monitor therapy. The Attrius is targeted for cardiac clinics and hospitals and is designed to meet the performance, budget and space constraints of the most demanding cardiologists. Attrius was named the "Most Innovative Device of 2010" by the renowned business research and consulting firm Frost & Sullivan.
Positron achieved significant advancements with the Company's new state-of-the-art coronary flow reserve (CFR) software, developed in collaboration with the University of Texas.
The CFR software, a clear differentiator for PET imaging compared to SPECT, was developed by a leading cardiologist and industry luminary Dr. K. Lance Gould and is considered to be a key driver in the upcoming growth in cardiac PET.
Positron is PET.
Company Website: http://www.positron.com
Share Structure
October 2017
Authorized Shares: 400,000,000 Common Shares
Outstanding Shares: 14,275,979 Common Shares (fully diluted)
Approximate Float: 4,000,000 Common Shares
Forward Looking Statements
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
DISCLAIMER: The Moderator owns a position in POSC. He has not been compensated by any party for any post regarding POSC, and has never been compensated by any company nor any party for any post regarding any stock. Moderator may buy, hold, or sell his position at any time without warning to any party. Posts are not meant as a solicitation to buy, sell, or hold any position in POSC, nor any other stock. Moderator may be buying, or selling, stock in POSC as he is posting. There is no guarantee that the Moderator may not immediately eliminate his position on any day at any time during market hours. Do not buy, hold, or sell based upon any post regarding this stock, or any other equity. Do your own Due Diligence, and buy, sell, or hold based upon your own due diligence.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |